SEMINAR OVERVIEW
This seminar series will provide updates on the diagnosis and treatment of chronic liver disease with a strong focus on patient care and symptom management. Teams of local, hepatology experts (physicians and advanced-practice providers) will deliver an interdisciplinary, team-based approach in a classroom setting that stresses interaction between participants and faculty.

To lower the barriers to participation and increase access, the program will be offered on Saturdays in twelve cities throughout the country beginning in December 2018. See the calendar of programs.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment and care management approaches for each.

Primary Biliary Cholangitis (PBC) is an old disease but one that is experiencing some major changes. A new treatment, Olopatadine (OCA), the first new drug for the disease in 20 years, is a breakthrough for patients who have had an incomplete response to Ursodiol (URSO).

Non-Alcoholic Steatohepatitis (NASH) is an epidemic in the US and is expected to be the major cause of cirrhosis in the coming decades as chronic Hepatitis C quickly wanes. There are many unmet needs associated with NASH including simple biomarkers and other non-invasive tests to help diagnose it and promising therapies coming out of research trials. Also there are new break-throughs in the treatment of Thrombocytopenia and NAFLD.

End Stage Liver Disease (ESLD) is expected to continue to grow in prevalence largely due to the burden of chronic viral hepatitis that exists in our population. As these patients age, a larger number will develop decompensation events such as variceal bleeding, hepatic encephalopathy, hyponatremia and renal failure.

Hepatocellular Carcinoma (HCC) is the most common form of liver cancer and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. New research is yielding some promising therapies to treat and/or reduce tumor size.

Don’t Miss Out On This National Program Coming To A City Near You!

PROGRAM HIGHLIGHTS
The conference will focus on the challenges of:
- Diagnosis and treatment of chronic liver disease;
- current and emerging drug and surgical therapies and incorporating new knowledge to improve patient outcomes

- Updated content based on the latest medical guidelines and clinical trial results
- Strong patient-focused educational sessions using evidence-based studies from the latest AASLD, EASL and DDW programs

- Interactive format that includes practical patient case review, small group discussion and the use of Audience Response technology to gauge opinion and build consensus

- Teams of local experts, comprised of physicians and advanced-practice clinicians, providing an interdisciplinary, team approach to treatment

- Participants can receive up to 6.0 AMA PRA Category 1 Credits™ or up to 71 nursing education credits

WHO SHOULD ATTEND
This program is especially developed for Hepatologists, Gastroenterologists, Internists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists.

These are the providers who are primarily tasked with caring for patients with chronic liver disease, both in the hospital and in the outpatient setting.

FUTURE EVENTS
- Raleigh, NC, May 4
- Washington, DC, June 15
- Denver, CO, June 22

SEMINAR OVERVIEW
This seminar series will provide updates on the diagnosis and treatment of chronic liver disease with a strong focus on patient care and symptom management. Teams of local, hepatology experts (physicians and advanced-practice providers) will deliver an interdisciplinary, team-based approach in a classroom setting that stresses interaction between participants and faculty.

To lower the barriers to participation and increase access, the program will be offered on Saturdays in twelve cities throughout the country beginning in December 2018. See the calendar of programs.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment and care management approaches for each.

Primary Biliary Cholangitis (PBC) is an old disease but one that is experiencing some major changes. A new treatment, Olopatadine (OCA), the first new drug for the disease in 20 years, is a breakthrough for patients who have had an incomplete response to Ursodiol (URSO).

Non-Alcoholic Steatohepatitis (NASH) is an epidemic in the US and is expected to be the major cause of cirrhosis in the coming decades as chronic Hepatitis C quickly wanes. There are many unmet needs associated with NASH including simple biomarkers and other non-invasive tests to help diagnose it and promising therapies coming out of research trials. Also there are new break-throughs in the treatment of Thrombocytopenia and NAFLD.

End Stage Liver Disease (ESLD) is expected to continue to grow in prevalence largely due to the burden of chronic viral hepatitis that exists in our population. As these patients age, a larger number will develop decompensation events such as variceal bleeding, hepatic encephalopathy, hyponatremia and renal failure.

Hepatocellular Carcinoma (HCC) is the most common form of liver cancer and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. New research is yielding some promising therapies to treat and/or reduce tumor size.
EDUCATIONAL OBJECTIVES

After attending this activity, participants should be able to:

- Summarize the causes of chronic liver disease and hepatic encephalopathy
- Comprehend the complexities of organ transplant procedures and waitlists
- Review the current therapies for PBC and clinical approaches for PSC
- Learn about diagnostic tests for NASH that may soon be in daily use
- Discuss the importance of liver biopsy for assessment of liver disease as well as less invasive tools and procedures
- Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number
- Discover why Immunotherapy is the new Method of Action for Hepatocellular Carcinoma
- Discuss treatment options for thrombocytopenia, including therapeutic alternatives to platelet transfusion
- Employ the progression pathways of Fatty Liver Disease to NASH to Liver Cancer to improve patient management processes and clinical outcomes.
- Utilize current clinical cases to improve diagnostic and treatment skills

SCHEDULE

7:30 am  Registration, Continental Breakfast & View Exhibits

8:00 am  Welcome and Pre-Test

8:20 am  End Stage Liver Disease: Treatment, Managing Complications and Transplant

- Staging, workup, and diagnosis of cirrhosis
- Medical care of the patient with end stage liver disease
- Liver Transplantation
- Listing criteria, MELD scores, exceptions and the transplant process
- Case Study 1 - Cirrhosis and Encephalopathy

9:20 am  Hepatocellular Carcinoma

- Screening diagnostic serum assays and imaging tests
- Diagnosis without histology
- Treatment and management options: Ablation, TACE and Surgery

10:00 am  Break & View Exhibits

10:15 am  Hepatocellular Carcinoma: New Systemic Treatment Options

- Current FDA-approved therapies
- New chemotherapy regimens in development and testing
- Immunotherapy as the new M.O.A. for HCC
- Case Study 2 - Diagnosis and Treatment of Hepatocellular Carcinoma

11:00 am  Primary Sclerosing Cholangitis (PSC)

- Epidemiology
- Ursodiol and Antibiotic Treatments
- Predicting Outcomes and Improving Survival

11:25 am  New Treatments for Primary Biliary Cholangitis (PBC)

- Causes and Markers of PBC
- Treatment Management
- Ursodeoxycholic Acid (UDCA) and Obeticholic Acid

12:00 pm  Lunch and View Exhibits

1:00 pm  The Best Use of Non-Invasive Imaging for Fibrosis Assessment

- Technologies, Procedures and Outcomes

1:30 pm  NAFLD, LAL-D and NASH

- Epidemiology, Demographics and Diagnosis
- Treatment options for Thrombocytopenia, including alternatives to platelet transfusion
- Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease

2:15 pm  Break & View Exhibits

2:30 pm  NASH Treatments in Development

- Current therapies for NASH
- Life style change as a therapy
- Drugs in clinical development for NASH
- Case Study 3 - NASH Diagnosis and Treatment

3:30 pm  Post Test and Adjourn at 3:45pm

Registration Information

Or call: University of Louisville CME & PD (502) 852-5329

Early Registration Regular Registration
Physicians and Clinical Pharmacists $95 $115
Nurses, Nurse Practitioners and PA’s $70 $90
Medical Residents & Fellows $60 $80

EDUCATION & PROFESSIONAL DEVELOPMENT designates this live activity for a maximum of 7.1 continuing education credits through University of Louisville Hospital, Louisville, KY. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

SPONSORS

The mission of the University of Louisville Continuing Medical Education and Professional Development program is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit http://louisville.edu/medicine/cme

The SC Liver Research Consortium (SCLR) is an organization of physicians specializing in hepatology and gastroenterology clinical research. SCLR’s mission is to team research sponsors and SCLR’s over 90 research sites together to provide faster, higher-quality research results compared to the current “conventional” sponsor-site arrangement. For more information visit www.scliver.com

DISCLOSURE

Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards. For more information, visit www.acme.org. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty, and others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial entity that they or their spouse/partner may have had within the past 12 months. Disclosure will be made to all participants at the conference location, prior to the commencement of the educational activity.

ACCRREDITATION

Joint Provider Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium, The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners & Physician Assistants - AANP and AAPA accept Category 1 credit from AMA PRA Category 1 Credit(s)** organizations accredited by ACCME.